These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26053647)

  • 1. FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing.
    Levy KD; Pratt VM; Skaar TC; Vance GH; Flockhart DA
    J Clin Pharmacol; 2015 Jul; 55(7):725-7. PubMed ID: 26053647
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA oversight of laboratory-developed tests will facilitate adoption of pharmacogenetic testing into routine clinical care.
    Hillebrenner E; Litwack E; Bradley P; Donigan K; Lowe T; Serrano K; Kelm K; Mansfield E; Gutierrez A
    J Clin Pharmacol; 2015 Jul; 55(7):728-30. PubMed ID: 26053648
    [No Abstract]   [Full Text] [Related]  

  • 3. US Food and Drug Administration regulatory oversight of laboratory-developed tests: Commentary on the draft guidance.
    Sidawy MK
    Cancer Cytopathol; 2015 Oct; 123(10):573-5. PubMed ID: 26042383
    [No Abstract]   [Full Text] [Related]  

  • 4. Laboratory-developed tests are not the practice of medicine.
    Allen JS
    MLO Med Lab Obs; 2015 Sep; 47(9):46. PubMed ID: 26495599
    [No Abstract]   [Full Text] [Related]  

  • 5. Understanding the Food and Drug Administration's Jurisdiction Over Laboratory-Developed Tests and Divisions Between Food, Drug, and Cosmetic Act-Regulated and Clinical Laboratory Improvement Amendments of 1988-Regulated Activities.
    Thompson BM; Scott BI; Boiani JA
    Clin Lab Med; 2016 Sep; 36(3):575-85. PubMed ID: 27514469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy?
    de Leon J; Spina E
    Expert Rev Clin Pharmacol; 2016; 9(3):351-4. PubMed ID: 26580456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facing the Inevitable: Being Prepared for Regulatory Requirements for Laboratory Developed Tests.
    D'Angelo R; Weiss R; Wolfe D; Chinnam R; Murat A; Gluesing J; Somers T
    Am J Clin Pathol; 2018 Apr; 149(6):484-498. PubMed ID: 29659675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA's framework for regulatory oversight of LDTs.
    Pathak B; Terry SF
    Genet Test Mol Biomarkers; 2014 Dec; 18(12):785-6. PubMed ID: 25469801
    [No Abstract]   [Full Text] [Related]  

  • 9. Laboratory-Developed Tests: A Legislative and Regulatory Review.
    Genzen JR; Mohlman JS; Lynch JL; Squires MW; Weiss RL
    Clin Chem; 2017 Oct; 63(10):1575-1584. PubMed ID: 28687634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FDA's Experience with Covid-19 Antibody Tests.
    Shuren J; Stenzel T
    N Engl J Med; 2021 Feb; 384(7):592-594. PubMed ID: 33605568
    [No Abstract]   [Full Text] [Related]  

  • 11. Precision medicine and the FDA's draft guidance on laboratory-developed tests.
    Hwang TJ; Lehmann LS; Kesselheim AS
    Nat Biotechnol; 2015 May; 33(5):449-51. PubMed ID: 25965745
    [No Abstract]   [Full Text] [Related]  

  • 12. Notification of highly abnormal laboratory results to doctors outside hospitals.
    Aakre KM; Hov GG; Skadberg O; Piehler A; Distante S; Hager HB
    Tidsskr Nor Laegeforen; 2013 Nov; 133(21):E1-6. PubMed ID: 24226343
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostics Reform and Harmonization of Clinical Laboratory Testing.
    Schreier J; Feeney R; Keeling P
    J Mol Diagn; 2019 Sep; 21(5):737-745. PubMed ID: 31075512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Notification of highly deviant biochemical analysis results].
    Aakre KM; Hov GG; Skadberg Ø; Piehler A; Distante S; Hager HB
    Tidsskr Nor Laegeforen; 2013 Nov; 133(21):2240-1. PubMed ID: 24226328
    [No Abstract]   [Full Text] [Related]  

  • 15. The push to reconcile the gap in LDT regulations.
    Farmer T
    MLO Med Lab Obs; 2015 Dec; 47(12):14-6. PubMed ID: 26742264
    [No Abstract]   [Full Text] [Related]  

  • 16. Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing.
    Haga SB; Kantor A
    Health Aff (Millwood); 2018 May; 37(5):717-723. PubMed ID: 29733708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Laboratory Improvement Amendments of 1988 (CLIA); Fecal Occult Blood (FOB) Testing. Final rule.
    ;
    Fed Regist; 2017 Oct; 82(202):48770-3. PubMed ID: 29090890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. US Food and Drug Administration Perspectives on Clinical Mass Spectrometry.
    Lathrop JT; Jeffery DA; Shea YR; Scholl PF; Chan MM
    Clin Chem; 2016 Jan; 62(1):41-7. PubMed ID: 26553791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The laboratory's role in pharmacogenetic testing.
    Oleschuck C
    MLO Med Lab Obs; 2008 May; 40(5):14-9. PubMed ID: 18567490
    [No Abstract]   [Full Text] [Related]  

  • 20. Expansion of pharmacogenomics into the community pharmacy: billing considerations.
    O'Connor SK; Michaels N; Ferreri S
    Pharmacogenomics; 2015; 16(3):175-80. PubMed ID: 25712181
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.